ADVFN Logo ADVFN

Wir konnten keine Ergebnisse für:
Stelle sicher, dass deine Schreibweise korrekt ist oder versuche deine Suche zu erweitern.

Trends

Toplisten

Es scheint, dass du nicht eingeloggt bist.
Klicke auf den Button unten, um dich einzuloggen und deine zuletzt angesehenen Aktien zu sehen.

Registrieren

Bereits Mitglied? Einloggen

Pepperstone

Jetzt Handeln

Pepperstone
Marktdaten
News
Werkzeuge
Märkte
Entdecken

Hot Features

Follow Feed

Vernetzen Sie sich mit Händlern und Investoren in unserer Follow-Feed-Community.

Optionen-Flow

Erkunden Sie umfassende Optionsdaten und nutzen Sie erweiterte Filter mit Options Flow.

Watchlist

Organisieren und überwachen Sie Ihre Aktien- und Vermögensbeobachtungsliste mit dem Monitor.
Anmelden Premium IconPremium Help Menu
DAX
19.906,08
-0,49%
S&P 500
5.942,47
1,26%
Dow Jones
42.732,13
0,80%
Euro vs US Dollar
1,03102
0,05%
Bitcoin
99.526,71
1,24%
Pepperstone
Advertisement
Registration Strip Icon for discussion Registrieren Sie sich, um in unseren aktiven Foren mit gleichgesinnten Anlegern zu diskutieren.
Registrieren
  1. Startseite
  2. Investieren
  3. Aktien
  4. USA
  5. NASDAQ

  6. Virax Biolabs Group Ltd (VRAX) Börsenkurse

Virax Biolabs Group Ltd

Virax Biolabs Group Ltd (VRAX)

NASDAQ
2,43
0,22
(9,95%)
Geschlossen 06 Januar 10:00PM
Verzögert um 15 Minuten
2,44
0,01
(0,41%)
Nach Börsenschluss: 1:55AM
Verzögert um 15 Minuten

Stärken Sie Ihr Portfolio: Diskussionen in Echtzeit und umsetzbare Handelsideen.

Premium

Wichtige Statistiken und Details

Current Price
2,44
Gebot
2,04
Fragen
2,96
Volumen
959.697
2,31 Tagesbereich 2,7293
0,60 52-Wochen-Bereich 8,9999
Marktkapitalisierung
10,59M
Handelsende
2,21
Handelsbeginn
2,35
Letzte Trade
200
@
2.44
(formt)
Letzter Handelszeitpunkt
Finanzvolumen
US$ 2.375.032
VWAP
2,4748
Durchschnittliches Volumen (3 Mio.)
1.868.874
Ausgegebene Aktien
4.340.000
Dividendenrendite
-
Kurs-Gewinn-Verhältnis
-1,59
Gewinn pro Aktie (EPS)
-1,55
Erlöse
156k
Nettogewinn
-6,73M

Über Virax Biolabs Group Ltd

Virax Biolabs Group Ltd is a innovative biotechnology company focused on the prevention, detection, diagnosis and risk management of viral diseases with a particular interest in the field of immunology. It is developing a proprietary T-Cell Test technology with the intention of providing an immunolo... Virax Biolabs Group Ltd is a innovative biotechnology company focused on the prevention, detection, diagnosis and risk management of viral diseases with a particular interest in the field of immunology. It is developing a proprietary T-Cell Test technology with the intention of providing an immunology profiling platform that assesses each individual's immune risk profile against major global viral threats. T-Cell testing is particularly effective in the diagnosis and therapeutics of COVID-19 as well as other threats including Hepatitis B, Malaria, Herpes and Human Papillomavirus. Mehr anzeigen

Sektor
In Vitro,in Vivo Diagnostics
Branche
In Vitro,in Vivo Diagnostics
Website
viraxbiolabs.com
Hauptsitz
Oxon, Gbr
Gegründet
-
Virax Biolabs Group Ltd is listed in the In Vitro,in Vivo Diagnostics sector of the NASDAQ with ticker VRAX. The last closing price for Virax Biolabs was US$2,21. Over the last year, Virax Biolabs shares have traded in a share price range of US$ 0,60 to US$ 8,9999.

Virax Biolabs currently has 4.340.000 shares in issue. The market capitalisation of Virax Biolabs is US$9,59 million. Virax Biolabs has a price to earnings ratio (PE ratio) of -1.59.

VRAX Neueste Nachrichten

Weitere Nachrichten

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

23 Dezember 2024
Edgar (US Regulatory)

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

17 Dezember 2024
Edgar (US Regulatory)

Virax Biolabs' CEO James Foster Issues Letter to Shareholders

Virax Biolabs' CEO James Foster Issues Letter to Shareholders PR Newswire LONDON, Dec. 17, 2024 LONDON, Dec. 17, 2024 /PRNewswire/ -- Virax Biolabs Group Limited (NASDAQ: VRAX) ("Virax" or the...

17 Dezember 2024
PR Newswire (US)

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

10 Dezember 2024
Edgar (US Regulatory)

Virax Biolabs Announces Agreement with Tebubio to Expand Distribution of ImmuneSelect Across the European Union, Norway, and Switzerland

Virax Biolabs Announces Agreement with Tebubio to Expand Distribution of ImmuneSelect Across the European Union, Norway, and Switzerland PR Newswire LONDON, Dec. 10, 2024 LONDON, Dec. 10, 2024...

10 Dezember 2024
PR Newswire (US)

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

20 November 2024
Edgar (US Regulatory)

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

31 Oktober 2024
Edgar (US Regulatory)

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

23 Oktober 2024
Edgar (US Regulatory)

Virax Biolabs Announces Distribution Agreement with Europa Biosite to Commercialize ImmuneSelect in the United Kingdom and Ireland

Virax Biolabs Announces Distribution Agreement with Europa Biosite to Commercialize ImmuneSelect in the United Kingdom and Ireland PR Newswire LONDON, Oct. 23, 2024 LONDON, Oct. 23, 2024...

23 Oktober 2024
PR Newswire (US)

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

30 September 2024
Edgar (US Regulatory)
Zeitraum †ÄnderungÄnderung %HandelsbeginnHochNiedrigDurchsch. VolumenVWAP
10.6838.63636363641.762.681.686244412.1408194CS
40.6939.42857142861.752.681.51435253562.12006558CS
120.6838.63636363641.763.621.4618688742.44543217CS
261.37128.0373831781.078.99990.961631542704.17396165CS
521.1386.25954198471.318.99990.619667763.73074196CS
156-197.56-98.782002900.6151613022.00677152CS
260-197.56-98.782002900.6151613022.00677152CS

VRAX - Frequently Asked Questions (FAQ)

What is the current Virax Biolabs share price?
The current share price of Virax Biolabs is US$ 2,44
How many Virax Biolabs shares are in issue?
Virax Biolabs has 4.340.000 shares in issue
What is the market cap of Virax Biolabs?
The market capitalisation of Virax Biolabs is USD 9,59M
What is the 1 year trading range for Virax Biolabs share price?
Virax Biolabs has traded in the range of US$ 0,60 to US$ 8,9999 during the past year
What is the PE ratio of Virax Biolabs?
The price to earnings ratio of Virax Biolabs is -1,59
What is the cash to sales ratio of Virax Biolabs?
The cash to sales ratio of Virax Biolabs is 68,52
What is the reporting currency for Virax Biolabs?
Virax Biolabs reports financial results in USD
What is the latest annual turnover for Virax Biolabs?
The latest annual turnover of Virax Biolabs is USD 156k
What is the latest annual profit for Virax Biolabs?
The latest annual profit of Virax Biolabs is USD -6,73M
What is the registered address of Virax Biolabs?
The registered address for Virax Biolabs is 30 BROADWICK STREET LONDON, W1F 8LX, OXON
What is the Virax Biolabs website address?
The website address for Virax Biolabs is viraxbiolabs.com
Which industry sector does Virax Biolabs operate in?
Virax Biolabs operates in the IN VITRO,IN VIVO DIAGNOSTICS sector

Beweger

Alle Anzeigen
  • Volumen
  • % Tops
  • % Flops
SymbolPreisVol.
FCUVFocus Universal Inc
US$ 0,9499
(174,93%)
260,93M
NITON2OFF Inc
US$ 2,6306
(145,85%)
358,28M
CRNCCerence Inc
US$ 19,33
(143,76%)
161,8M
KITTNauticus Robotics Inc
US$ 3,8249
(140,56%)
104,8M
ACONAclarion Inc
US$ 0,2984
(110,14%)
305,64M
HWHHWH International Inc
US$ 0,4621
(-28,80%)
7,43M
SMSTDefiance Daily Target 2x Short MSTR ETF
US$ 5,69
(-26,30%)
24,77M
RAINRain Enhancement Technologies Holdco Inc
US$ 5,59
(-23,42%)
161,15k
PTLEPTL Ltd
US$ 9,35
(-23,30%)
1,04M
NXUNXU Inc
US$ 0,725868
(-22,78%)
7,59M
NITON2OFF Inc
US$ 2,6306
(145,85%)
358,28M
TGLTreasure Global Inc
US$ 0,382
(101,58%)
337,5M
ACONAclarion Inc
US$ 0,2984
(110,14%)
305,64M
FCUVFocus Universal Inc
US$ 0,9499
(174,93%)
260,93M
NVDANVIDIA Corporation
US$ 144,47
(4,45%)
230,01M

Foren

Foren anzeigen
Keine Diskussionen Gefunden.
Neuen Thread Erstellen

Kürzlich von Ihnen besucht

NASDAQ
VRAX
Virax Biolabs
NYSE
JAS
Jo Ann Stores
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

Deutschland
Unternehmen
Geschäft
Popular
App herunterladen
App Store
Google Play

Support: +44 (0) 203 8794 460 | support@advfn.de

Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen

© 2025 ADVFN PLC - Alle Rechte vorbehalten